Generic Name:
fostamatinib
Project Status:
Complete
Therapeutic Area:
Chronic immune thrombocytopenia
Manufacturer:
Medison Pharma Canada
Brand Name:
Tavalisse
Project Line:
Reimbursement Review
Project Number:
SR0701-000
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
Recommendation Type:
Do not reimburse
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.